Document is current
Any future updates will be listed below
-
Authors
Yang, Xiangcai
Yin, Wei
Xu, Mengmeng
Tusa, Ignazia
Menconi, Alessio
Dai, Yan
Ding, Qinglin
Wang, Guoqiang
Foley, Kevin P.
Rovida, Elisabetta
Ying, Weiwen
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG-21349)
Fondazione Cassa di Risparmio di Firenze
European Union-NextGenerationEU-National Recovery and Resilience Plan, Mission 4 Component 2-Investment 1.5-THE-Tuscany Health Ecosystem (ECS00000017-CUP B83C22003920001)
Beneficientia Stiftung
- License Information
-
More Information
Article History
Received: 4 September 2025
Accepted: 18 January 2026
First Online: 3 February 2026
Declarations
:
: Animal experiments were conducted by Pharmaron Beijing Co., Ltd. (Beijing, China), under their Institutional Animal Care and Use Committee approval (IACUC, ON-CELL-XEN-06012022). All the procedures in this study related to animal handling, care, and the treatment were performed according to guidelines approved by the IACUC of Pharmaron following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). In addition, all portions of this study were performed at Pharmaron and adhered to the study protocol provided or approved by the sponsor and applicable standard operating procedures (SOPs).
: Not applicable.
: The authors declare no potential conflicts of interest.
: We declare a patent application (WO 2022/078350 A1) filed by Ranok Therapeutics (Hangzhou) Co. LTD.
